Milestone Scientific Q3 revenue dips, net loss narrows
Milestone Scientific's Q3 revenue decreased slightly due to lower domestic dental sales, but net loss narrowed to $1.2 million from $1.5 million. The company improved operating loss by 23% through cost-reduction initiatives. Milestone expects improved margins and revenue stability from operational transformation and is advancing its reimbursement strategy for broader adoption of CompuFlo®. Analysts rate the stock as a 'buy' with a median 12-month price target of $2.00, significantly above its current price.
)
Overview
- Milestone Scientific Q3 revenue decreased slightly due to lower domestic dental sales
- Operating loss improved by 23% due to cost-reduction initiatives
- Net loss narrowed to $1.2 mln from $1.5 mln in Q3 2024
Outlook
- Company expects improved margins and revenue stability from operational transformation
- Milestone Scientific advancing reimbursement strategy for broader adoption of CompuFlo®
- Company sees growing interest in CompuFlo® from hospitals and international distributors
Result Drivers
- COST MANAGEMENT - Co reduced operating expenses by over $0.5 mln through disciplined cost management and restructuring
- DENTAL SEGMENT EXPANSION - Co expanded direct sales programs in North America and secured new international registrations for STA® System
- MEDICAL SEGMENT GROWTH - Growing utilization of CompuFlo® disposables and progress in reimbursement strategies boosted recurring revenue
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 EPS -$0.01
Q3 Net -$1.20
Income mln
Q3 Gross $1.60
Profit mln
Q3 -$1.10
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the advanced medical equipment & technology peer group is “buy”
- Wall Street’s median 12-month price target for Milestone Scientific Inc is $2.00, about 82% above its November 12 closing price of $0.36
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
